MSD to support Transgene and BioInvent led oncolytic virus clinical trial 28-Jun-2022 By Jane Byrne MSD will supply Keytruda (pembrolizumab) in a phase 1/2a clinical trial for the treatment of patients with solid tumors, as part of an agreement with Transgene and BioInvent.
Transgene and AZ to explore virus-based immunotherapies 02-May-2019 By Ben Hargreaves The two companies will work to co-develop five oncolytic virus candidates through a collaborative research, option and licensing agreement.
